BRIEF published on 08/14/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Releases 2025 Half-Year Report Relief Therapeutics RLF-TD011 RLF-OD032 2025 Half-Year Report NeuroX Partnership
PRESS RELEASE published on 08/14/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 1 year 1 month ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year 3 months ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year 3 months ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
Published on 09/18/2026 at 22:00, 2 hours 12 minutes ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 3 hours 37 minutes ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 9 hours 42 minutes ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 10 hours 42 minutes ago Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer
Published on 09/18/2026 at 18:44, 5 hours 28 minutes ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 5 hours 59 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 6 hours 2 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 6 hours 5 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:34, 5 hours 38 minutes ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 1 day 6 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
